Variation in Sp1 binding sites correlates with expression of survivin in breast cancer

Molecular Medicine Reports

Volumn 10, Issue 3, 2014, Pages 1395-1399

  Xu, Qing ^a   Liu, Mei ^a   Xu, Ningzhi ^a   Zhu, Hongxia ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Breast cancer; Promoter region; Sp1 binding sites; Survivin

Indexed keywords

SURVIVIN; TRANSCRIPTION FACTOR SP1; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; SP1 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER TISSUE; DNA SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; APOPTOSIS; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

APOPTOSIS; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETIC VARIATION; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 84905456628     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2371     Document Type: Article

References (47)

1. Li F and Ling X: Survivin study: an update of 'what is the next wave'? J Cell Physiol 208: 476-486, 2006. (Pubitemid 44141872)
2. Li F: Survivin study: what is the next wave? J Cell Physiol 197: 8-29, 2003.
3. Jha K, Shukla M and Pandey M: Survivin expression and targeting in breast cancer. Surg Oncol 21: 125-131, 2012.
4. Altieri DC: New wirings in the survivin networks. Oncogene 27: 6276-6284, 2008.
5. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70, 2008.
6. Guha M and Altieri DC: Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8: 2708-2710, 2009.
7. Waligórska-Stachura J, Jankowska A, Waśko R, et al: Survivin - prognostic tumor biomarker in human neoplasms - review. Ginekol Pol 83: 537-540, 2012.
8. Sarti M, Pinton S, Limoni C, et al: Differential expression of testin and survivin in breast cancer subtypes. Oncol Rep 30: 824-832, 2013.
9. Dedić Plavetić N, Jakić-Razumović J, Kulić A and Vrbanec D: Prognostic value of proliferation markers expression in breast cancer. Med Oncol 30: 523, 2013.
10. Song J, Su H, Zhou YY and Guo LL: Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biol 34: 2053-2062, 2013.
11. Xu C, Yamamoto-Ibusuki M, Yamamoto Y, et al: High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level. Breast Cancer: Sep 12, 2012 (Epub ahead of print).
12. Li X, Dang X and Sun X: Expression of survivin and VEGF-C in breast cancer tissue and its relation to lymphatic metastasis. Eur J Gynaecol Oncol 33: 178-182, 2012.
13. Adamkov M, Kajo K, Vybohova D, Krajcovic J, Stuller F and Rajcani J: Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma. Neoplasma 59: 30-37, 2012.
14. Kapoor S: Beyond pancreatic carcinoma: The close relationship between survivin levels and prognosis in systemic malignancies. World J Clin Oncol 3: 80-81, 2012.
15. Johnson ME and Howerth EW: Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol 41: 599-607, 2004. (Pubitemid 39573750)
16. Gazouli M, Tzanakis N, Rallis G, et al: Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 24: 145-150, 2009.
17. Li XB, Li SN, Yang ZH, Cao L, Duan FL and Sun XW: Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. DNA Cell Biol 32: 236-242, 2013.
18. Xu Y, Fang F, Ludewig G, Jones G and Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23: 419-429, 2004. (Pubitemid 38981976)
19. Boidot R, Vegran F, Jacob D, et al: The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosomes Cancer 47: 299-308, 2008. (Pubitemid 351323759)
20. Li F and Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J 344: 305-311, 1999. (Pubitemid 30011584)
21. Xu R, Zhang P, Huang J, Ge S, Lu J and Qian G: Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 356: 286-292, 2007. (Pubitemid 46413162)
22. Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV and Sverdlov ED: Functional significance of a putative Sp1 transcription factor binding site in the survivin gene promoter. Biochemistry (Mosc) 73: 1183-1191, 2008.
23. Zhang G, Zhu H, Wang Y, et al: Krüppel-like factor 4 represses transcription of the survivin gene in esophageal cancer cell lines. Biol Chem 390: 463-469, 2009.
24. Li Y, Xie M, Yang J, et al: The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple Sp1 binding sites in the proximal promoter. Oncogene 25: 3296-3306, 2006. (Pubitemid 43846314)
25. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001. (Pubitemid 32878711)
26. Chin K, DeVries S, Fridlyand J, et al: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541, 2006. (Pubitemid 44854748)
27. King CR, Kraus MH and Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976, 1985. (Pubitemid 16248488)
28. Banerji S, Cibulskis K, Rangel-Escareno C, et al: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409, 2012.
29. Sjöblom T, Jones S, Wood LD, et al: The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274, 2006. (Pubitemid 44571966)
30. Wood LD, Parsons DW, Jones S, et al: The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113, 2007. (Pubitemid 350134889)
31. Kan Z, Jaiswal BS, Stinson J, et al: Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873, 2010.
32. Usary J, Llaca V, Karaca G, et al: Mutation of GATA3 in human breast tumors. Oncogene 23: 7669-7678, 2004. (Pubitemid 39424925)
33. Ly M, Valent A, Diallo G, et al: Gene copy number variations in breast cancer of Sub-Saharan African women. Breast 22: 295-300, 2013.
34. Orsetti B, Courjal F, Cuny M, Rodriguez C and Theillet C: 17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene 18: 6262-6270, 1999.
35. Kalikin LM, Frank TS, Svoboda-Newman SM, Wetzel JC, Cooney KA and Petty EM: A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors. Oncogene 14: 1991-1994, 1997. (Pubitemid 27217812)
36. Cheng ZJ, Hu LH and Huang SJ: Correlation of -31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng 27: 258-263, 2008 (In Chinese).
37. Jang JS, Kim KM, Kang KH, et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60: 31-39, 2008. (Pubitemid 351434465)
38. Wang YH, Chiou HY, Lin CT, et al: Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 73: 670-674, 2009.
39. Yang X, Xiong G, Chen X, et al: Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 135: 1341-1349, 2009.
40. Borbély AA, Murvai M, Szarka K, et al: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60: 303-306, 2007. (Pubitemid 46447748)
41. Wierstra I: Sp1: emerging roles - beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 372: 1-13, 2008.
42. Grant SF, Reid DM, Blake G, Herd R, Fogelman I and Ralston SH: Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet 14: 203-205, 1996. (Pubitemid 26338805)
43. Liu W, Innocenti F, Wu MH, et al: A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 65: 46-53, 2005. (Pubitemid 40070794)
44. Miao X, Yu C, Tan W, et al: A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 63: 3987-3990, 2003. (Pubitemid 36917916)
45. Yu C, Pan K, Xing D, et al: Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 62: 6430-6433, 2002. (Pubitemid 35364100)
46. Cheng Q, Ling X, Haller A, et al: Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 3: 179-197, 2012.
47. Estève PO, Chin HG and Pradhan S: Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 282: 2615-2625, 2007.